Ustekinumab in Crohn's disease: Real‐world outcomes from the Sicilian network for inflammatory bowel diseases

BACKGROUND AND AIM: Ustekinumab is approved in Europe for the treatment of moderate to severe Crohn's disease (CD). Italian real‐life data are scarce, so the aim of this study was to assess the effectiveness and safety of ustekinumab in an Italian cohort of CD patients. METHODS: Data of patient...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:JGH Open
Päätekijät: Viola, Anna, Muscianisi, Marco, Macaluso, Fabio S, Ventimiglia, Marco, Cappello, Maria, Privitera, Antonino C, Magnano, Antonio, Pluchino, Dario, Magrì, Giovanni, Ferracane, Concetta, Mocciaro, Filippo, Garufi, Serena, Giuffrida, Enrica, Costantino, Giuseppe, Fiocco, Gabriele, Grova, Mauro, Guida, Laura, Alibrandi, Angela, Orlando, Ambrogio, Fries, Walter
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Wiley Publishing Asia Pty Ltd 2021
Aiheet:
Original Articles
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7936616/
https://ncbi.nlm.nih.gov/pubmed/33732883
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jgh3.12502
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia